Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$17.51M, compared with -$24.2M a year earlier. Trailing-twelve-month EBITDA was -$75.47M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +20.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$17.51M+4.6% QoQ
- Last fiscal yearDec 2025
- -$82.16M+20.0% YoY
- LTMMar 2026
- -$75.47M+22.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.7% | +100.0% | +72.3 pp |
| 1 year | +20.0% | +100.0% | +80.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (82.16M) USD
- Year-over-year change
- +20.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (82.16M) | +20.0% |
| FY2024 | 2024-12-31 | (102.66M) | +11.0% |
| FY2023 | 2023-12-31 | (115.4M) | -0.4% |
| FY2022 | 2022-12-31 | (114.95M) | -67.3% |
| FY2021 | 2021-12-31 | (68.7M) | — |
EBITDA vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 EBITDA of -$75.47M is the 6th highest of the 11 companies compared; the peer median is -$74.23M.
- Its year-over-year change of +22.0% is the 5th highest of 11, against a peer median of +9.7%.
- EBITDA amounts to 33540.9% of revenue for TNYA, versus a peer median of 480.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $73.43M | +298.8% | — | 505.0% | |
| LTM Mar 2026 | -$46.56M | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -$50.77M | +11.7% | — | — | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Mar 2026 | -$72.53M | +7.7% | — | 257.0% | |
| LTM Mar 2026 | -$75.47M | +22.0% | — | 33540.9% | |
| LTM Mar 2026 | -$75.93M | +0.5% | — | 547.9% | |
| LTM Mar 2026 | -$76.13M | +39.6% | — | 455.3% | |
| LTM Mar 2026 | -$79.77M | -33.1% | — | 3956.7% | |
| LTM Mar 2026 | -$111.97M | +23.4% | — | 999.5% | |
| LTM Mar 2026 | -$112.54M | -37.5% | — | 308.4% | |
| Peer median (excluding TNYA) | -$74.23M | +9.7% | — | 480.2% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| Gross Profit | (4.03M) | (8.71M) | (8.69M) | (8.47M) | (8.44M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| Selling, General & Admin | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| Operating Expenses | 68.78M | 116.91M | 122.51M | 107.48M | 84.9M |
| Depreciation & Amortization | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBITDA | (68.7M) | (114.95M) | (115.4M) | (102.66M) | (82.16M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (72.81M) | (125.62M) | (131.19M) | (115.95M) | (93.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Income Before Tax | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| EPS (Diluted) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| Weighted Avg Shares | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Weighted Avg Shares (Diluted) | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.